Specifically, HOTTIP increases the ability of pancreatic cancer cells to withstand both cisplatin and gemcitabine by either upregulating HOXA13 or downregulating miR-137, a miRNA that initially makes cells more sensitive to cisplatin (Jiang et al. 2023). Here, HOTTIP is linked to familial pancreatic carcinoma.